Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valopicitabine (NM283) Alone or With Pegylated Interferon in Treatment-Naive Chronic Hepatitis C
NCT00118768Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of valopicitabine in hepatitis C (HCV) (5 arms), sponsored by Merck & Co. Primary endpoints: Sustained Virologic Response at 72 weeks and HCV RNA Reduction at 48 weeks. Started Aug 2005; status: completed.
02
Drugs
valopicitabine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00118768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118768.